Dabigatran Concentration: Variability and Potential Bleeding Prediction In “Real-Life” Patients With Atrial Fibrillation-Reference-Cited by-同舟云学术

Dabigatran Concentration: Variability and Potential Bleeding Prediction In “Real-Life” Patients With Atrial Fibrillation

Published:2015-06-11 Issue:5 Volume:117 Page:323-329
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Šinigoj Petra¹,Malmström Rickard E.²,Vene Nina¹,Rönquist-Nii Yuko³,Božič-Mijovski Mojca¹,Pohanka Anton³,Antovic Jovan P.⁴,Mavri Alenka¹

Affiliation:

1. Department of Vascular Diseases; University Medical Centre; Ljubljana Slovenia

2. Department of Medicine Solna; Karolinska Institutet & Clinical Pharmacology; Karolinska University Hospital; Stockholm Sweden

3. Department of Laboratory Medicine Huddinge; Division of Clinical Pharmacology; Karolinska Institutet & Clinical Pharmacology; Karolinska University Hospital; Stockholm Sweden

4. Department of Coagulation Research; Institute for Molecular Medicine and Surgery; Karolinska Institutet & Department of Clinical Chemistry; Karolinska University Hospital; Stockholm Sweden

Funder

Javna Agencija za Raziskovalno Dejavnost RS

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcpt.12417/fullpdf

Reference20 articles.

1. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association;Camm;Eur Heart J,2012

2. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate;Stangier;Clin Pharmacokinet,2008

3. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor;Stangier;Clin Appl Thromb Hemost,2009

4. E.M.A. EU - Summary of Product Characteristic: PRADAXA http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000829/WC500041059.pdf

5. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis;Baglin;J Thromb Haemost,2013

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential use of laboratory monitoring during individualizing the dosage of direct oral anticoagulants - a literature review;Vnitřní lékařství;2023-10-26

2. The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam;Scientific Reports;2023-06-07

3. Impact of Direct Oral Anticoagulant Concentration on Clinical Outcomes in Asian Patients with Atrial Fibrillation;Clinical Pharmacology & Therapeutics;2023-05-17

4. DOACs plasma levels in relation to clinical outcome. How far have we come?;Thrombosis Research;2023-05

5. Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes;Journal of Thrombosis and Thrombolysis;2022-12-09